Biocept Awarded Patent in Australia for the Use of Antibodies in Microchannels to Capture Circulating Tumor Cells and Other Rare Cells
"Our liquid biopsy platform has the distinct advantage of using both CTCs and circulating tumor DNA (ctDNA) to detect and monitor biomarkers associated with cancer," said
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the management, diagnosis and treatment of cancer, the ability of our
tests to provide clinically actionable information to oncologist and their patients, and our ability to expand the distribution of our liquid biopsy platform worldwide, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-awarded-patent-in-australia-for-the-use-of-antibodies-in-microchannels-to-capture-circulating-tumor-cells-and-other-rare-cells-300393179.html
SOURCE
News Provided by Acquire Media